Table 2.

Seroconversion Rates Over Time for 10 Subjects Identified as Spike and Nucleoprotein Seronegative (S-IgG and N-IgG) at Baseline.

Overall Cohort	D0 (n = 60)	D14PP (n = 54)	D28PP (n = 54)	D14PB (n = 49)	D28PB (n = 49)	M6PP (n = 54)	M9PP (n = 52)	M12PP (n = 51)
S-IgG- and N-IgG- at baseline	10	8	8	9	8	10	10	10
S-IgG	0 (0.00%)	3 (37.5%)	4 (50.0%)	7 (77.8%)	6 (75.0%)	8 (80.0%)	9 (90.0%)	9 (90.0%)
S-IgM	1 (10.0%)	3 (37.5%)	0 (0.00%)	1 (11.1%)	3 (37.5%)	1 (10.0%)	0 (0.00%)	0 (0.00%)
S-IgA	1 (10.0%)	3 (37.5%)	2 (25.0%)	2 (22.2%)	2 (25.0%)	6 (60.0%)	6 (60.0%)	6 (60.0%)
N-IgG	0 (0.00%)	2 (25.0%)	2 (25.0%)	3 (33.3%)	5 (62.5%)	4 (40.0%)	2 (20.0%)	6 (60.0%)
N-IgM	1 (10.0%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (10.0%)	2 (20.0%)

Table 2 presents the counts (n) and corresponding proportions (percentages) of subjects exhibiting seropositivity for IgG, IgM, and IgA antibody isotypes against both the spike and nucleoprotein at each respective time point. The displayed data pertains explicitly to a subset of subjects initially identified as seronegative for antibodies targeting spike and nucleoprotein at baseline (denoted as baseline S-IgG- and N-IgG-). The table also provides the total number of subjects from the main cohort and those classified as S-IgG- and N-IgG- at baseline.